Cytotoxic effect of targeted biodegradable epothilone B and rapamycin co-loaded nanocarriers on breast cancer cells.
Biocompatible Materials
/ chemistry
Breast Neoplasms
/ drug therapy
Cell Death
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
Drug Carriers
/ chemistry
Drug Delivery Systems
Epothilones
/ pharmacology
Female
Humans
Micelles
Nanoparticles
/ chemistry
Proton Magnetic Resonance Spectroscopy
Sirolimus
/ pharmacology
PLA-PEG-BIO micelles
breast cancer cells
cytotoxicity
epothilone B
rapamycin
Journal
Journal of biomedical materials research. Part A
ISSN: 1552-4965
Titre abrégé: J Biomed Mater Res A
Pays: United States
ID NLM: 101234237
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
03
03
2021
received:
07
10
2020
accepted:
08
03
2021
pubmed:
16
3
2021
medline:
24
2
2022
entrez:
15
3
2021
Statut:
ppublish
Résumé
The new therapeutic solutions for breast cancer treatment are needed, for example, combined therapy consisted of several drugs that characterize different mechanisms of action and modern drug delivery systems. Therefore, we used combination of epothilone B (EpoB) and rapamycin (Rap) to analyze the cytotoxic effect against breast cancer cells (MCF-7; MDA-MB-231). Also, the effect of drugs co-delivered in bioresorbable micelles functionalized with biotin (PLA-PEG-BIO; poly(lactide)-co-poly(ethylene glycol)-biotin) was studied. The comparison of effects of the mixture of free drugs and the micelles co-loaded with EpoB and Rap revealed a significant decrease in the cell metabolic activity and survival. Moreover, the dual drug-loaded PLA-PEG-BIO micelles enhanced the cytotoxicity of EpoB and Rap against the tested cells as compared with the free drugs. The blank PLA-PEG-BIO micelles did not affect the tested cells. We expect that mixture of EpoB and Rap may be promising in breast cancer treatment and PLA-PEG-BIO micelles as carrier of these two drugs can be applicable for successful targeted delivery.
Substances chimiques
Biocompatible Materials
0
Drug Carriers
0
Epothilones
0
Micelles
0
epothilone B
UEC0H0URSE
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693-1700Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1):34-42.
Němcová-Fürstová V, Kopperová D, Balušíková K, et al. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol. 2016;310:215-228.
Cheng H, Huang H, Huang G. Synthesis and antitumor activity of epothilone B. Eur J Med Chem. 2018;157:925-934.
Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27(13):2278-2287.
Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of Rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004;10(20):7031-7042.
Shin DH, Kwon GS. Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. J Control Release. 2017;268:176-183.
Shin DH, Kwon GS. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy. Int J Pharm. 2017;518(1):307-311.
Hill EK, Dizon DS. Medical therapy of endometrial Cancer. Drugs. 2012;72(5):705-713.
Tian X, Yin H, Zhang S, et al. Bufalin loaded biotinylated chitosan nanoparticles: an efficient drug delivery system for targeted chemotherapy against breast carcinoma. Eur J Pharm Biopharm. 2014;87(3):445-453.
Vineberg JG, Zuniga ES, Kamath A, Chen Y-J, Seitz JD, Ojima I. Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a Taxoid-Camptothecin combination chemotherapy. J Med Chem. 2014;57(13):5777-5791.
Kang YJ, Park DC, Shin H-H, Park J, Kang S. Incorporation of thrombin cleavage peptide into a protein cage for constructing a protease-responsive multifunctional delivery Nanoplatform. Biomacromolecules. 2012;13(12):4057-4064.
Bui DT, Nicolas J, Maksimenko A, Desmaële D, Couvreur P. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chem Commun. 2014;50(40):5336-5338.
Su J, Chen F, Cryns VL, Messersmith PB. Catechol polymers for pH-responsive, targeted drug delivery to cancer cells. J Am Chem Soc. 2011;133(31):11850-11853.
Tang B, Peng Y, Yue Q, et al. Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer. Eur J Med Chem. 2020;193:112204.
Jelonek K, Li SM, Kasperczyk J, Wu XH, Orchel A. Effect of polymer degradation on prolonged release of paclitaxel from filomicelles of polylactide/poly(ethylene glycol) block copolymers. Mater Sci Eng C. 2017;75:918-925.
Danhier F, Magotteaux N, Ucakar B, Lecouturier N, Brewster M, Préat V. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel. Eur J Pharm Biopharm. 2009;73(2):230-238.
Li C, Wang W, Xi Y, et al. Design, preparation and characterization of cyclic RGDfK peptide modified poly(ethylene glycol)-block-poly(lactic acid) micelle for targeted delivery. Mater Sci Eng C. 2016;64:303-309.
Noh W-C, Mondesire WH, Peng J, et al. Determinants of Rapamycin sensitivity in breast Cancer cells. Clin Cancer Res. 2004;10(3):1013-1023.
Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle. 2011;10(22):3948-3956.
Kalantar H, Sabetkasaei M, Shahriari A, et al. The effect of Rapamycin on oxidative stress in MCF-7 and MDA MB-231 human breast Cancer cell lines. Jundishapur J Nat Pharm Prod. 2016;11(3):e38177.
Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008;27(2):S43-S51.
Gopalakrishnan K, Venkatesan S, Low ESH, Hande MP. Effects of rapamycin on the mechanistic target of rapamycin (mTOR) pathway and telomerase in breast cancer cells. Mutat Res Genet Toxicol Environ Mutagen. 2018;836:103-113.
Liu Q, Zhou X, Li C, Zhang X, Li CL. Rapamycin promotes the anticancer action of dihydroartemisinin in breast cancer MDA-MB-231 cells by regulating expression of Atg7 and DAPK. Oncol Lett. 2018;15(4):5781-5786.
Tengku Din TADA-A, Seeni A, Khairi W-NM, Shamsuddin S, Jaafar H. Effects of rapamycin on cell apoptosis in MCF-7 human breast cancer cells. Asian Pacific J Cancer Prev. 2014;15(24):10659-10663.
Abrams SL, Steelman LS, Shelton JG, et al. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle. 2010;9(9):1839-1846.
Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8(3):249-258.
Blanco E, Sangai T, Wu S, et al. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014;22(7):1310-1319.
Tian W, Liu J, Guo Y, Shen Y, Zhou D, Guo S. Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cells. J Mater Chem B. 2015;3(7):1204-1207.
Wang J, Li S, Han Y, et al. Poly(ethylene glycol)-Polylactide micelles for Cancer therapy. Front Pharmacol. 2018;9:202.
Deshmukh AS, Chauhan PN, Noolvi MN, et al. Polymeric micelles: basic research to clinical practice. Int J Pharm. 2017;532(1):249-268.
Gothwal A, Khan I, Gupta U. Polymeric micelles: recent advancements in the delivery of anticancer drugs. Pharm Res. 2016;33(1):18-39.
Biswas S, Kumari P, Lakhani PM, Ghosh B. Recent advances in polymeric micelles for anti-cancer drug delivery. Eur J Pharm Sci. 2016;83:184-202.
Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108-121.
Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for Cancer chemotherapy. Biomacromolecules. 2014;15(6):1955-1969.
Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem. 2004;98(10):1625-1633.
Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs. 2008;9(12):1277-1286.
Jelonek K, Kasperczyk J, Li S, et al. Bioresorbable filomicelles for targeted delivery of betulin derivative - in vitro study. Int J Pharm. 2019;557:43-52.
Ren WX, Han J, Uhm S, et al. Recent development of biotin conjugation in biological imaging, sensing, and target delivery. Chem Commun. 2015;51(52):10403-10418.